MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

Plus, news about Mer­ck, Ori­on, Tonix, Freeflow and Y-mAbs Ther­a­peu­tics: Tra­con Phar­ma­ceu­ti­cals seeks ‘strate­gic al­ter­na­tives’ af­ter PD-L1 fails Ph2 tri­al: In an 82-per­son sar­co­ma study

Roche’s breast can­cer com­bi­na­tion of in­avolis­ib plus pal­bo­ci­clib and ful­ves­trant showed off new da­ta Fri­day, with the com­pa­ny tout­ing a 57% re­duc­tion in the risk

In the mid­dle of 2023, Richard Baty­cky told a cou­ple of his fel­low ex­ec­u­tives at No­cion Ther­a­peu­tics to con­sid­er look­ing for roles else­where. He wasn’t